Depression as a Comorbidity in Behçet's Syndrome

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 51st of 261 in Pharmacology & Pharmacy
  • 78th of 252 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.769
5 - Year: 3.923

Depression as a Comorbidity in Behçet's Syndrome

Author(s): N P de Oliveira Ribeiro, A R de Mello Schier, T M Pessoa, V M Pereira, S Machado, O Arias-Carrión, A E Nardi and A C Silva

Affiliation: Institute of Psychiatry - Federal University of Rio de Janeiro. Laboratory of Panic and Respiration. Rua Visconde de Pirajá, 407/702. Rio de Janeiro, RJ. CEP 22410-003. Brazil

Abstract

Behçet's syndrome (BD) is a controversial, chronic, and episodic condition that is autoimmune in origin and causes systemic vasculitis in the arteries and genital veins. BD is consistently associated with depression [1,2], with an incidence of 86% upon the first appearance of symptoms and disorders of the disease [6]. However, few studies have looked at depression and other psychiatric disorders, such as anxiety, in the context of comorbidity with BD. The aim of this review is to identify articles that focus on the relation between BD and depression as a comorbidity. This Research was conducted by two independent researchers using four databases, were found forty nine references using the keywords "Behçet's Syndrome" and "depression", excluding articles that were not in english, case studies in children and adolescents, clinical cases, literature reviews, and articles that did not have depression as a comorbidity. The reviewed studies reveal a consistently high incidence of depression in the BD population, even when compared with other chronic pathologies including Rheumatoid Arthritis and Psoriasis, although there was a limitation in the use of scales and other tools for assessment and control of comorbid symptoms, moreover there are no studies linking the drugs used in the BD treatment of each patient and the symptoms present in each case. This review clearly shows the lack of research in which depression scores are analyzed in the relation to the medications used by individual patients. Additionally, the use of additional scales is necessary to increase the knowledge about the nature and consequences of depression as a comorbidity of BD


Purchase Online Rights and Permissions

Article Details

Volume: 13
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1871527313666140612114115
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science